Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY PM Suga Vows to Work towards Annual Price Revisions: Diet Policy Speech
October 27, 2020
-
REGULATORY 1st Working Group Meeting for Prioritization of “Stable Supply Medicines” Set for Early November
October 26, 2020
-
BUSINESS Novartis Looks to Solidify Presence in Multiple Sclerosis Arena with Mayzent, then Ofatumumab
October 23, 2020
-
BUSINESS GSK Sets Up Oncology Biz Unit in Japan; Multiple Late-Stage Assets in Pipeline
October 22, 2020
-
REGULATORY PMDA Sees Studies on Preventive Effect as a “Must” for Coronavirus Vaccines: Official
October 21, 2020
-
BUSINESS Pfizer, BioNTech Begin Japan PI/II Study for COVID-19 Vaccine
October 21, 2020
-
BUSINESS LEO Pharma’s Atopic Dermatitis Program Lags as PMDA Requests Japanese Data, but Growth Goal Intact
October 20, 2020
-
REGULATORY Japan Cannot Boast of Its Development Status of COVID-19 Vaccines/Drugs: LDP Health Committee Chair
October 20, 2020
-
REGULATORY 3 Mega Pharma-Drugs Now Approved in Japan with Continuous Manufacturing, Japan Players Could Follow Suit Soon: PMDA Specialist
October 19, 2020
-
BUSINESS Fujifilm Eyes Avigan Use in Mild and Severe COVID-19 Cases: Exec
October 19, 2020
-
BUSINESS (Update) Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
-
BUSINESS Chugai, Roche Discussing Japan Development of Regeneron's COVID-19 Antibody Cocktail
October 16, 2020
-
BUSINESS Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
-
BUSINESS Japan Sees Improved LHRH Agonist Supply as Leuprorelin Output Rises; Shipment Curbs for Substitutes Lifted
October 15, 2020
-
REGULATORY MHLW to Make “Comprehensive Decision” on Off-Year Drug Pricing Plan: Minister
October 15, 2020
-
BUSINESS Big 4 Wholesalers Now Suspected to Have Rigged Drug Prices in 2016 Too
October 14, 2020
-
BUSINESS Nippon Zoki Eyes Alzheimer’s as New R&D Focus, First Up Is Label Expansion for Pain Med
October 13, 2020
-
BUSINESS Despite Price Cuts, Dupixent Netting Bullish Sales to Become Sanofi’s New Flagship
October 12, 2020
-
REGULATORY MOF Pitches Off-Year Re-Pricing for “All Products” Including Patented Meds, Eyes Adjustment Rate Revision Too
October 9, 2020
-
BUSINESS Sumitomo Dainippon Rejigs Organization to Become Top CNS Player in Japan, Sets 50 Billion Yen Near-Term Goal
October 8, 2020
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…